Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALT02 (Trastuzumab Biosimilar) vs Herceptin in Healthy Volunteers
NCT03242239Phase 1Completed
- Sponsor
- Alteogen
- Start
- Feb 2016
- Primary completion
- Aug 2016
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
01
Overview
Phase 1, randomised, double-blind trial of QL1701 in HER2-positive breast cancer and HER2-positive gastric cancer (3 arms), sponsored by Alteogen. Primary endpoint: Area under the concentration-time curve from time zero to infinity at 43 days. Started Feb 2016; status: completed.
02
Drugs
QL1701
03
Conditions
HER2-positive breast cancerHER2-positive gastric cancer
Beyond the preview
Go deeper on NCT03242239.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03242239.